Neuromedin U-25 (human) (trifluoroacetate salt)

Neuromedin U (NMU) is a neuropeptide first demonstrated to drive smooth muscle contraction. Translated as a 174 amino acid propeptide, NMU is cleaved to different lengths in different animals. It has diverse receptor-mediated roles in vivo, as it regulates feeding, vasoconstriction, nociception, and bone remodeling and contributes to obesity, cancer and septic shock. NMU-25 is the active form of NMU in humans. It binds with high affinity to receptors on human left ventricle and coronary artery (K_Ds = 0.26 and 0.11 nM, respectively), eliciting endothelium-independent vasoconstriction. NMU-25 also suppresses glucose-stimulated insulin secretion in human islets, and this effect is lost in NMU R165W mutants, resulting in early-onset obesity.

[1] JD MITCHELL  AP D  JJ Maguire. Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S[J]. British Journal of Pharmacology, 2009, 158 1: 87-103. DOI: 10.1111/j.1476-5381.2009.00252.x
[2] HANNAH C GREENWOOD K G M Stephen R Bloom. Peptides and their potential role in the treatment of diabetes and obesity.[J]. Review of Diabetic Studies, 2011, 8 3: 355-368. DOI: 10.1900/rds.2011.8.355
[3] J. MITCHELL. Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system.[J]. Cardiovascular Research, 2008, 81 2 1: 353-361. DOI: 10.1093/cvr/cvn302
[4] RONALD W ALFA. Suppression of Insulin Production and Secretion by a Decretin Hormone.[J]. Cell metabolism, 2018: 479. DOI: 10.1016/j.cmet.2018.01.003